Skip to content

Marc Döring

Partner

London

Doering Marc
Marc Döring

Partner

London

Marc has over 20 years’ experience of handling IP disputes, specialising in patent litigation and co-ordinating global patent enforcement and defence cases. Marc graduated with a degree in Biotechnology before going on to study law. His patent litigation experience covers a wide range of technologies including hi-tech, mechanical engineering, chemical and medical devices, with a particular focus on pharmaceutical and biologics patent litigation including blockbuster small molecule litigation against generic companies, antibodies and immunotherapies.

Clients and peers describe Marc as "A superb all-round litigator, a master tactician who engages in the fine technical details of the case" (Chambers & Partners 2018); "We always know we have a fight on our hands when he is on the other side, and he is pragmatic - he knows which battles to fight." (Chambers & Partners 2019); a "superb litigator who combines top-level litigation nous with boundless charm" (Legal 500 2018), and "A life sciences virtuoso who relishes a bet-the-firm battle" (IAM Patent 1000, 2018).

He is recommended as a Leading Individual for IP/Patent Litigation by The Legal 500 (‘Hall of Fame’), Chambers & Partners, The International Who's Who of Patent Lawyers, The International Who's Who of Life Sciences Lawyers, MIP's Expert Guide to the World's Leading Patent Law Practitioners, MIP Stars Handbook, IAM Patent 1000 and London Super Lawyers

Marc writes and speaks on intellectual property issues regularly. He is also a member of The Lawyers' Christian Fellowship.

Other noteworthy experience includes advising:

  • Bayer in various contentious patent issues, including proceedings (i) relating to Genentech’s dosage regime patent for treating intraocular neovascular disease using an anti-VEGF antibody (Eylea®), (ii) against Gedeon Richter concerning Bayer's oral female contraceptive pill patents regarding Yasmin®, (iii) against Janssen-Cilag concerning Bayer's patent relating to anti-TNF alpha monoclonal antibodies and Janssen’s infliximab/Remicade® product, (iv) the defence of Bayer’s patents relating to their anticoagulant product, Xarelto®, (vi) the defence of Bayer’s patents relating to their anti-cancer product, Nexavar®, (vii) enforcement of Bayer’s cropscience patents against Finchimica, and (viii) enforcement of Bayer’s animal health patents against Ceva Santé Animale.
  • Eli Lilly in proceedings against Teva regarding Teva’s European Patents which relate to antibodies for the prevention or treatment of migraine, and Lilly’s Emgality® product.
  • Frog Education in arbitration relating to a copyright and confidential information dispute against Netcompany A/S relating to Frog Education’s proprietary software, technical documentation and source code.
  • Imperial Brands in various contentious patent issues, including acting on behalf of Fontem Ventures (Imperial Brands’ subsidiary) in proceedings against Philip Morris, Japan Tobacco and others regarding Fontem’s e-cigarette patents.
  • LEO Pharma in proceedings (i) against Sandoz in relation to LEO’s patents for a new crystal form of vitamin D analogue (Dovonex®), including obtaining a preliminary injunction upheld on appeal, and (ii) against Teva relating to LEO's patents for a pharmaceutical composition comprising a vitamin D analogue and corticosteroid (Dovobet®) overturning a first instance decision of obviousness on appeal.
  • Leading investment bank on a breach of confidential information and copyright dispute with another leading investment bank in relation to an investment analyst team who had been recruited by our client.
  • Major multinational pharmaceutical company on the enforcement of its patents on a pan-European basis relating to its platelet inhibitor.
  • Redwood Technologies (developer of world-leading communications technology) on a breach of confidential information and copyright dispute with a senior programme developer.
  • Procter & Gamble in various contentious patent issues including proceedings (i) against Omron Healthcare in relation to P&G’s patents concerning oral healthcare products, (ii) against Unilever in relation to P&G’s patents concerning laundry detergent products (Ariel 3-in-1 pods®), and (iii) against Wilkinson Sword and Edgewell Personal Care Company relating to Gillette’s patents concerning Gillette’s MACH3® and VENUS® razors.
  • OrbusNeich in proceedings against Boston Scientific in relation to OrbusNeich’s stent patents.

Experience highlights

News & insights

What brand owners should know about design rights in the UK

Publications: 21 JANUARY 2020

What is the biggest obstacle preventing brand owners from enforcing their design rights?

Brand owners and inventors tend to be up to speed on trademarks and patents which can lead to the design rights being left behind. Insufficient knowledge of the system and how it works is contributing to the lack of design filings and enforcement. Global Head of IP David Stone talks about the things that are in place to change this, including building an awareness of what design rights business owners have available to them.

Read more
Abstract image of metal

Publications: 13 JANUARY 2020

The von der Leyen Commission

The European Commission led by Ursula von der Leyen took office on 1 December 2019, following changes required as a result of the European Parliament rejecting three of the candidate Commissioners originally put forward. 

Read more

News: 09 JANUARY 2020

Global trends in private M&A 2020

We have recently produced a client presentation on global trends in private M&A. Our findings draw on an in-depth analysis of more than 1,250 private M&A deals that A&O has advised on globally over the last eight years, looking at deal dynamics, execution risks and deal terms. This has given us exceptional insight into global and regional trends in market practice.

Read more
A person holding a test tube containing cannabis leaves

Publications: 29 NOVEMBER 2019

Flying high

As more countries liberalise their cannabis policies, there has been a rapid increase in the number of registered IP rights as competitors seek to establish their places in the market.

Read more

Office

London

Allen & Overy LLP
One Bishops Square
London
E1 6AD

View office →

Qualifications

Professional

Admitted as a Solicitor (Ireland), 2017

Admitted as a Solicitor Advocate, Higher Courts Civil Proceedings, 2004

Admitted as a Solicitor (England and Wales), 1997

Admitted as a Solicitor (Hong Kong), 1997

Academic

Diploma, IP Law and Practice, Bristol University, 1998

Diploma, Legal Practice Course, College of Law, 1994

Diploma, Common Professional Examination, College of Law, 1993

BSc (Hons) Biotechnology, Sheffield University, 1991

Recognition

Awards

Client Choice Award for Intellectual Property

Patents in the UK, International Law Office, 2016

Read more

European Life Sciences team of the year

Managing Intellectual Property (MIP) Global Awards 2014

Read more

Published Work

  • Döring M., and Thompson L. (2019) "Flying high" Patents and cannabis. Intellectual Property Magazine, November 2019
  • Döring M., and Thompson L. (2019) "Cannabinoid patenting – a rolling stone?" The Patent Lawyer, July/August 2019
  • Döring M., Fox J., Thompson L., and Potts B (2018) “UK Threats: Worldwide Consequences?” European Intellectual Property Review 40, Issue 2
  • Döring M., Feldges J., and Lim D. (2017) “Editing the Future: A Brief Introduction to CRISPR”, The Licensing Journal, Volume 73 No. 4
  • Döring M., and Lim D. (2017) “Questions about CRISPR”, Intellectual Property Magazine, April 2017 p.47-49
  • Döring M., and Trigg R. (2017) “Is there a future for a CRISPR patent pool?”, IP Pro Patents
  • Döring M., Woolgar A., and Thompson L. (2016) “Review of the Year - UK Patent Litigation in 2016”, Intellectual Property Magazine
  • Döring M, Kamstra G, Scott-Ram, N, Shead A, and Wixon H. (2002) “Patents on Biotechnological Inventions: The EC Directive”, Book by Sweet & Maxwell